Clinical Trials

GastrointestinalOther solid neoplasm

386 enrolled

Resectable Colon Cancer

NCT07543744 2026-04-22

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

180 enrolled

770 enrolled 13 charts 2 FDA

Colorectal Neoplasms

NCT04083235 2026-04-20

NAPOLI 3

Phase 3 Completed

Metastatic Adenocarcinoma of the Pancreas

NCT06131840 2026-04-20

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

914 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT06447662 2026-04-20

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06586515 2026-04-20

MOONRAY-01

630 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06792695 2026-04-20

CANTOR

Phase 2 Recruiting

120 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06997497 2026-04-20

KANDLELIT-012

477 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT07318805 2026-04-20

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

260 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05239741 2026-04-17

MK-3475-C66

100 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT06544655 2026-04-17

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

213 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT07409272 2026-04-16

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

614 enrolled

Pancreatic Neoplasms

NCT06820463 2026-04-15

AndroMETa-CRC

Phase 2 Recruiting

390 enrolled

Colorectal Neoplasms

NCT05379595 2026-04-13

OrigAMI-1

Phase 1/2 Recruiting

225 enrolled

Colorectal Neoplasms

NCT06469944 2026-04-13

MK-3475-06C

Phase 1/2 Recruiting

160 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06662786 2026-04-13

OrigAMI-2

1,000 enrolled

Colorectal Neoplasms

NCT06750094 2026-04-13

OrigAMI-3

700 enrolled

Colorectal Neoplasms

NCT07431281 2026-04-13

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

2,130 enrolled

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT07265674 2026-04-09

Beacon-BTC

480 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05253651 2026-04-07

MOUNTAINEER-03

400 enrolled

Colorectal Neoplasms

NCT07228832 2026-04-06

HARMONi-GI3

600 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT03505320 2026-04-03

ILUSTRO

143 enrolled

Phase 3 Active not recruiting

Neoplasms, Stomach Neoplasms

NCT05568095 2026-04-02

STAR-221

1,040 enrolled